Non-small cell lung cancer (NSCLC) is characterized by molecular heterogeneity with
diverse immune cell infiltration patterns, which has been linked to therapy sensitivity and …

Lung cancer is a highly heterogeneous disease. Cancer cells and cells within the tumor
microenvironment together determine disease progression, as well as response to or …

Single-cell technologies have revealed the complexity of the tumour immune
microenvironment with unparalleled resolution,,,,,,,–. Most clinical strategies rely on …

Background Malignant transformation and progression of cancer are driven by the co-
evolution of cancer cells and their dysregulated tumor microenvironment (TME). Recent …

Background Conventional immunohistochemistry technologies were limited by the inability
to simultaneously detect multiple markers and the lack of identifying spatial relationships …

Tumor-infiltrating myeloid cells (TIMs) comprise monocytes, macrophages, dendritic cells,
and neutrophils, and have emerged as key regulators of cancer growth. These cells can …

To guide the design of immunotherapy strategies for patients with early stage lung tumors,
we developed a multiscale immune profiling strategy to map the immune landscape of early …

Background Immunotherapy has revolutionized cancer treatment, but most patients are
refractory to immunotherapy or acquire resistance, with the underlying mechanisms …

A thorough interrogation of the immune landscape is crucial for immunotherapy strategy
selection and prediction of clinical responses in non-small-cell lung cancer (NSCLC) …

Understanding the role of the tumor microenvironment (TME) in lung cancer is critical to
improving patient outcomes. We identified four histology-independent archetype TMEs in …